VivoSim Labs, Inc. (VIVS) is a Healthcare stock trading at $0.29 (as of 2026-08-21), with a market capitalization of $4.25M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California.
VivoSim Labs develops a proprietary 3D tissue bioprinting platform using NovoGen Bioprinters, and advances its clinical candidate FXR314 in inflammatory bowel disease (focused on ulcerative colitis), with value likely tied to clinical progress and platform-enabled development outcomes.
The core profit model is development progress, primarily driven by advancing FXR314 in phase 2/3 for ulcerative colitis, supported by its NovoGen bioprinting system and related 3D tissue and bio-ink technologies.
Business quality (Weak): Company business and key product-stage fact (FXR314 phase 2/3 for ulcerative colitis) are clear, but no reportable segments or operating KPIs were provided.
| Price | $0.29 |
| Market Cap | $4.25M |
| EV / EBITDA | -0.2 |
| Price / Book | -1.81 |
| Price / Sales | 37.92 |
| FCF Yield | -238.3% |
| Revenue (TTM) | $131000.00 |
| Net Margin | -10567.2% |
| Return on Equity | 525.9% |
| Current Ratio | 1.70 |
| Revenue Growth (YoY) | -9.0% |
| EPS Growth (YoY) | 214.7% |
| FCF Growth (YoY) | 14.3% |
| Altman Z-Score | -71.90 (distress) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | GEODE CAPITAL MANAGEMENT, LLC ($52697.00) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Keith E. Murphy |
| Employees | 14 |
| Country | US |
| IPO Date | 2012-02-14 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.